Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1Genitourinary 1

Conditions

Pancreatic Neoplasms 406Carcinoma, Non-Small-Cell Lung 147Urinary Bladder Neoplasms 87Breast Neoplasms 84Cholangiocarcinoma 83Lung Neoplasms 78Neoplasm Metastasis 67Neoplasms 64Biliary Tract Neoplasms 58Nasopharyngeal Carcinoma 53Ovarian Neoplasms 46Sarcoma 43Recurrence 39Gallbladder Neoplasms 39Hodgkin Disease 34Lymphoma, Large B-Cell, Diffuse 33Lymphoma 32Carcinoma, Transitional Cell 29Bile Duct Neoplasms 24Adenocarcinoma 23Fallopian Tube Neoplasms 19Carcinoma, Hepatocellular 19Adenocarcinoma of Lung 18Triple Negative Breast Neoplasms 17Lymphoma, Non-Hodgkin 17Liver Neoplasms 17Nasopharyngeal Neoplasms 16Lymphoma, Extranodal NK-T-Cell 16Carcinoma 16Non-Muscle Invasive Bladder Neoplasms 15

Interventions

Cyclophosphamide 81fludarabine phosphate 77Peripheral Blood Stem Cell Transplantation 62Mycophenolic Acid 55Tacrolimus 54Whole-Body Irradiation 52Busulfan 51Antilymphocyte Serum 45Cyclosporine 41fludarabine 36Methotrexate 32Filgrastim 32Melphalan 30Radiotherapy 25Methylprednisolone 19Cytarabine 17Cord Blood Stem Cell Transplantation 17Sirolimus 15Azacitidine 15Granulocyte Colony-Stimulating Factor 14Alemtuzumab 14thymoglobulin 13Flow Cytometry 13Etoposide 13Cyclosporins 13Specimen Handling 10Biopsy 10Thiotepa 9Psychiatric Rehabilitation 9Decitabine 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Myeloproliferative Disorders × Gemcitabine × Clear all
NCT00588666 2016-01-22

Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
51 enrolled 7 charts
GenitourinaryMyeloid

Carcinoma, Transitional Cell, Myeloproliferative Disorders, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡